Back

Single cell RNA-seq reveals immunosuppressive gastric stem-like cancer cells as a poor prognostic factor

Lee, H. K.; Ang, K. S.; Chevrier, M.; Goh, M.; Ling, J.; Koh, V.; Zhang, X.; Tan, J. C.; Lee, N.; Erdal Irac, S.; Lim, Z. M.; Lum, J.; Tay, A.; Antoine Dutertre, C.; Tang, C.; Wong, C.; Lau, M. C.; Lim, C. J.; Chuah, S. W. J.; Lim, S.; Yeong, J. P. S.; Chew, V.; Larbi, A.; Singhal, A.; Poidinger, M.; Ng, M. C. H.; Wu Howland, S.; Tan, P.; Ginhoux, F.; So, J.; Yong, W. P.; Chen, J.

2020-10-23 immunology
10.1101/2020.10.23.351726 bioRxiv
Show abstract

ObjectiveGastric cancer (GC) tumors are highly heterogenous with different subpopulations of epithelial cells. We employed single cell RNA sequencing (scRNA-seq) to dissect the heterogeneity and identified subpopulations of cancer cells with stem-like properties. We further investigated their resistance to oxaliplatin chemotherapy and their contribution to gastric cancer outcome. DesignWe performed scRNA-seq on FACS sorted epithelial and immune cells from paired samples of GC tumors and normal adjacent tissues. We identified two epithelial subpopulations (STMN1+IQGAP3+ and STMN1+IQGAP3-) with stem-like properties. We characterized and compared them to known healthy gastric stem cell populations. We also cultivated GC derived organoids to study the chemoresistance of similarly marked populations. Lastly, we employed immunohistochemistry (IHC) staining to ascertain the predicted immunosuppressive interactions. ResultsThe STMN1+IQGAP3+ subpopulation showed a higher tumor mutation burden, upregulated proliferative pathways and transcriptomically resembled proliferative healthy gastric isthmus stem cells. The STMN1+IQGAP3- subpopulation were comparatively quiescent and transcriptomically resembled enteroendocrine cells. Both transcriptomic signatures were associated with worse mortality than other epithelial subpopulations with the quiescent being associated with the poorest patient survival. GC tissue derived organoids were dominated by STMN1+IQGAP3+ cells but the STMN1+IQGAP3- compartment was more resistant to chemotherapy. We also verified the likely suppression of CD8 T cell cytotoxicity by STMN1+IQGAP3+ cells through the NECTIN2/TIGIT interaction. ConclusionsCancer cells with stem-like characteristics are associated with poor survival through chemoresistance and immunosuppression. Reactivating the immune system through checkpoint blockade is an opportunity to eliminate these cells. What is already known on this topicMultiple gastric stem cell populations have been identified and linked to tumor initiation in rodent-based studies. However, none of them have been conclusively proven in human tumors. Isolating and characterizing tumor cells with stem-like properties will help shed light on their possible origin and possible mitigation strategies. What this study addsHere we identified two sets of stem-like gastric cancer cells that are associated with poorer patient prognosis. One set is highly proliferative and exhibits oxaliplatin susceptibility. It also engages in immunosuppressive interactions such as NECTIN2/TIGIT. The other set is quiescent and highly resistant to oxaliplatin. How this study might affect research, practice or policyThe transcriptome signatures of the identified stem-like cells can aid in patient prognosis and identify patients who can benefit from checkpoint blockade therapy to reactivate their immune response towards gastric cancer cells.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancer Letters
35 papers in training set
Top 0.1%
15.4%
2
Gut
40 papers in training set
Top 0.1%
9.9%
3
Gastroenterology
42 papers in training set
Top 0.1%
7.4%
4
eLife
5828 papers in training set
Top 16%
6.9%
5
Nature Communications
5641 papers in training set
Top 30%
4.4%
6
Cell Reports
1498 papers in training set
Top 10%
4.1%
7
Clinical and Translational Medicine
31 papers in training set
Top 0.1%
3.3%
50% of probability mass above
8
Cancer Cell
42 papers in training set
Top 0.5%
2.4%
9
npj Precision Oncology
53 papers in training set
Top 0.6%
2.4%
10
Genome Medicine
183 papers in training set
Top 2%
2.4%
11
Genomics, Proteomics & Bioinformatics
172 papers in training set
Top 0.9%
2.0%
12
iScience
1154 papers in training set
Top 16%
1.8%
13
BMC Biology
265 papers in training set
Top 2%
1.7%
14
Oncogene
85 papers in training set
Top 1%
1.5%
15
Cell Reports Medicine
153 papers in training set
Top 2%
1.5%
16
Cancer Immunology Research
35 papers in training set
Top 0.6%
1.4%
17
Computational and Structural Biotechnology Journal
242 papers in training set
Top 5%
1.2%
18
Cancers
213 papers in training set
Top 4%
1.1%
19
Cancer Research Communications
51 papers in training set
Top 1%
1.1%
20
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 1%
1.1%
21
Journal of Experimental Medicine
119 papers in training set
Top 3%
0.9%
22
PLOS ONE
5266 papers in training set
Top 60%
0.9%
23
International Journal of Cancer
49 papers in training set
Top 1%
0.6%
24
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.8%
0.6%
25
Science Advances
1243 papers in training set
Top 32%
0.6%
26
OncoImmunology
24 papers in training set
Top 0.7%
0.6%
27
Communications Biology
993 papers in training set
Top 33%
0.6%
28
Cell Death & Disease
126 papers in training set
Top 4%
0.6%
29
Scientific Reports
3612 papers in training set
Top 77%
0.6%